Asia Economy | Reporter Lee Kwan-joo firstname.lastname@example.org
Published date : July 11th, 2022
[Reporter Lee Kwan-joo of Asia Economy] BioPlus announced on the 11th that it has obtained a special import license from China’s Hainan Boao Lecheng International Medical Tourism Pilot Zone for two hyaluronic acid filler products from China’s Hainan Drug Supervision Administration.
Products that have obtained permission are medical beauty hyaluronic acid skin fillers such as “DeneB,” which is applied to the chest and hips, and “Skin Plus HYAL Implant,” which is applied to the face such as forehead, nose, and chin. According to this permission, BioPlus plans to start beauty treatments by importing products directly through its own beauty plastic surgery franchise hospital, which opened in Ziming Boao International Hospital in February.
Bioplus aims to promote clinical approval of NMPA (China’s National Drug Administration) fast-track (fast-track screening) in mainland China from next year, sell it throughout China by December next year, and open 30 beauty-plastic franchise hospitals in China within the next five years.
An official from BioPlus said, “China is forming a global medical market, and in particular, the field of cosmetic surgery is recording high growth every year.” An official also said, “If sales in China begin in earnest in the future, the company’s performance and competitiveness will be further enhanced.”
Reporter Lee Kwan-joo email@example.com